Loading
A phase 2 trial of Docetaxel and Gemcitabine in bladder & urothelial cancer, run by Relmada Therapeutics, Inc., now recruiting.
A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC is a phase 2 interventional study registered as NCT06663137 by Relmada Therapeutics, Inc., with 70 participants planned, started 2024-08-01 and due to reach its primary completion in 2027-11. Interventions recorded: NDV01 intravesical controlled release formulation of gemcitabine and docetaxel.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Docetaxel, Gemcitabine and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Docetaxel, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.